Avastin Gains New Ovarian Cancer Indication

Share this content:
FDA has approved Avastin for the treatment of platinum-resistant, recurrent ovarian cancer.
FDA has approved Avastin for the treatment of platinum-resistant, recurrent ovarian cancer.

Genentech announced that the Food and Drug Administration (FDA) has approved Avastin (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer.

The new approval was based on results from the Phase 3 AURELIA study, a multicenter, randomized, open-label study that evaluated women with platinum-resistant, recurrent, epithelial ovarian, primary peritoneal, or fallopian tube cancer, who had received no more than two anticancer regimens prior to start of the trial (n=361). Patients were randomized to one of six treatment arms (paclitaxel, topotecan, or pegylated liposomal doxorubicin with or without Avastin).

The study's primary endpoint was investigator-assessed progression free survival (PFS). Patients treated with Avastin + chemotherapy saw a median PFS of 6.8 months (95% CI 5.6, 7.8) vs. 3.4 months (95% CI 2.1, 3.8) in the chemotherapy alone group (HR 0.38, P<0.0001). The Avastin + chemotherapy group also demonstrated a hgiher median overall survival (OS), a secondary endpoint (16.6 months vs. 13.3 months; HR 0.89, 95% CI 0.69, 1.14).

RELATED: AVASTIN (bevacizumab) Drug Showcase

Avastin, an angiogenesis inhibitor, is already approved for the treatment of the following cancers: persistent, recurrent, or metastatic cervical cancer in combination with paclitaxel and cisplatin, or paclitaxel and topotecan; first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel; metastatic colorectal carcinoma, in combination with 5-FU-based chemotherapy for first- or second-line treatment; or in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based therapy for second-line treatment in patients who have progressed on a first-line Avastin-containing regimen; glioblastoma, as a single agent for patients with progressive disease following prior therapy; and metastatic renal cell carcinoma (mRCC) in combination with interferon alfa.

For more information call (800) 821-8590 or visit Avastin.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs